Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jan;131(1):193-199.
doi: 10.1007/s11060-016-2288-5. Epub 2016 Oct 21.

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

Mark R Gilbert  1 , Stephanie L Pugh  2 , Ken Aldape  3 , A Gregory Sorensen  4 , Tom Mikkelsen  5 , Marta Penas-Prado  6 , Felix Bokstein  7 , Young Kwok  8 , R Jeffrey Lee  9 , Minesh Mehta  8
Affiliations
Clinical Trial

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

Mark R Gilbert et al. J Neurooncol. 2017 Jan.

Abstract

Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. Eligibility included age ≥18, recurrent or progressive GBM after standard chemoradiation. Treatment was intravenous bevacizumab 10 mg/kg and either irinotecan (CPT) 125 mg/m2 every 2 weeks or temozolomide (TMZ) 75-100 mg/m2 day 1-21 of 28 day cycle. Accrual goal was 57 eligible patients per arm. Primary endpoint was 6 month progression-free survival (6-m PFS); a predetermined rate of ≥35 % to declare efficacy. 60 eligible patients were enrolled on TMZ arm and 57 patients on CPT arm. Median age was 56, median KPS was 80. For TMZ arm, the 6-m-PFS rate was 39 % (23/59); for the CPT arm, the 6-m-PFS rate was 38.6 % (22/57). Objective responses: TMZ arm had 2 (3 %) CR, 9 (16 %) PR; CPT arm had 2 (4 %) CR, 13 (24 %) PR. Overall there was moderate toxicity: TMZ arm with 33 (55 %) grade 3, 11 (18 %) grade 4, and 1 (2 %) grade 5 (fatal) toxicities; CPT arm had 22 (39 %) grade 3, 7 (12 %) grade 4, and 3 (5 %) grade 5 toxicities. The 6-m-PFS surpassed the predetermined efficacy threshold for both arms, corroborating the efficacy of bevacizumab and CPT and confirming activity for bevacizumab and protracted TMZ for recurrent/progressive GBM, even after prior temozolomide exposure. Toxicities were within anticipated frequencies with a moderately high rate of venous thrombosis, moderate hypertension and one intracranial hemorrhage.

Keywords: Anti-angiogenic treatment; Combination therapy; Glioblastoma; Randomized trial.

PubMed Disclaimer

Conflict of interest statement

Dr. Gilbert reports personal fees and non-financial support from Merck, personal fees from Genentech Roche, personal fees from Abbvie, personal fees from Wellcome Trust, and personal fees from Foundation Medicine, outside the submitted work. Dr. Sorensen reports employment by Siemens Healthcare, outside the submitted work. Dr. Mikkelsen has a consulting or advisory role with Roche Genentech and has received honoraria, travel and research funding from Roche Genentech, outside the submitted work. Dr. Penas-Prado has received research funding from Bayer, Genentech, Glaxo, and Novartis, outside the submitted work. Dr. Mehta has a leadership role with Pharmacyclics, stock or ownership interest in Pharmacyclics, consulting or advisory roles with Cavion, Elekta, Novartis and Novocure, and has received research funding from Novocure and Novellos, outside the submitted work.

Figures

Figure 1
Figure 1
Study Schema
Figure 2
Figure 2
CONSORT Diagram
Figure 2
Figure 2
CONSORT Diagram
Figure 3
Figure 3
Progression Free and Overall Survival
Figure 3
Figure 3
Progression Free and Overall Survival
See this image and copyright information in PMC

References

    1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17:2572. - PubMed
    1. Wen PY, Kesari S. Malignant gliomas in adults. The New England journal of medicine. 2008;359:492–507. - PubMed
    1. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nature reviews Neuroscience. 2007;8:610–622. - PubMed
    1. Visted T, Lund-Johansen M. Progress and challenges for cell encapsulation in brain tumour therapy. Expert opinion on biological therapy. 2003;3:551–561. - PubMed
    1. Jain RK. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science. 2005;307:58–62. - PubMed

Publication types

MeSH terms